Schistosome sirtuins as drug targets

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

• 1 Fenwick A, Webster JP, Bosque-Oliva E et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology 136(13), 1719–1730 (2009).
  Medline CASGoogle Scholar
• 2 Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 21(6), 659–667 (2008).
  Medline CASGoogle Scholar
• 3 Berriman M, Haas B, Loverde PT et al. The genome of the blood fluke Schistosoma mansoni. Nature 460(7253), 352–358 (2009).
  Medline CASGoogle Scholar
• 4 Zhou Y, Zheng H, Chen X et al. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 460(7253), 345–351(2009).
  Medline CASGoogle Scholar
• 5 Young ND, Jex AR, Li B et al. Whole-genome sequence of Schistosoma haematobium. Nat. Genet. 44(2), 221–225 (2012).
  Medline CASGoogle Scholar
• 6 Cabezas-Cruz A, Lancelot J, Caby S, Oliveira G, Pierce RJ. Epigenetic control of gene function in schistosomes: a source of therapeutic targets? Front. Genet. 5, 317 (2014).• Reviews current knowledge of epigenetic mechanisms in schistosomes and evaluates their potential as therapeutic targets.
  MedlineGoogle Scholar
• 7 Herranz D, Munoz-Martin M, Canamero M et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 1, 3 (2010).
  MedlineGoogle Scholar
• 8 Kaeberlein M. Lessons on longevity from budding yeast. Nature 464(7288), 513–519 (2010).
  Medline CASGoogle Scholar
• 9 Libert S, Guarente L. Metabolic and neuropsychiatric effects of calorie restriction and sirtuins. Annu. Rev. Physiol. 10, 669–684 (2013).
  Google Scholar
• 10 Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 6, 1399–1416 (2013).•• A comprehensive and recent review of the roles of human sirtuins as cancer promoters or repressors and the potential for therapeutic intervention.
  Medline CASGoogle Scholar
• 11 Greiss S, Gartner A. Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation. Mol. Cells 28(5), 407–415 (2009).• Revises the phylogeny of the sirtuins and highlights the differences in the complement of sirtuins in different species.
  Medline CASGoogle Scholar
• 12 Costantini S, Sharma A, Raucci R, Costantini M, Autiero I, Colonna G. Genealogy of an ancient protein family: the sirtuins, a family of disordered members. BMC Evol. Biol. 13, 1–19 (2013).
  MedlineGoogle Scholar
• 13 Religa A, Waters A. Sirtuins of parasitic protozoa: in search of function(s). Mol. Biochem. Parasitol. 185(2), 71–88 (2012).• Explores the roles of sirtuins in parasitic protozoa and emphasizes their interest as drug targets.
  Medline CASGoogle Scholar
• 14 Zheng W. Sirtuins as emerging anti-parasitic targets. Eur. J. Med. Chem. 59, 132–140 (2013).
  Medline CASGoogle Scholar
• 15 Pierce R, Dubois-Abdesselem F, Lancelot J, Andrade L, Oliveira G. Targeting schistosome histone modifying enzymes for drug development. Curr. Pharm. Des. 18(24), 3567–3578 (2012).
  Medline CASGoogle Scholar
• 16 Lancelot J, Caby S, Dubois-Abdesselem F et al. Schistosoma mansoni sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl. Trop. Dis. 7, e2428 (2013).•• Characterizes the sirtuins of S. mansoni and shows that sirtuin inhibitors induce apoptosis and death of the parasites, emphasizing their potential as anti-schistosomal drugs.
  MedlineGoogle Scholar
• 17 Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273(2), 793–798 (2000).
  Medline CASGoogle Scholar
• 18 Cavalier-Smith T. “The origin of Fungi and pseudofungi”. In: Evolutionary biology of the fungi: symposium of the british mycological society. Rayner ADM, Brasier CM, Moore D (Eds). Cambridge Univ. Press, Cambridge, UK, 339–353 (1987).
  Google Scholar
• 19 Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizationos and functions of human SIRT proteins. Mol. Biol. Cell. 16(10), 4623–4635 (2005).
  Medline CASGoogle Scholar
• 20 North BJ, Verdin E. Interphase nuleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS ONE 2(8), e784, (2007).
  MedlineGoogle Scholar
• 21 Vaquero A, Scher MB, Lee DH et al. SirT2 is a histone deacetylase with preference for histone H4Lys 16 during mitosis. Genes Dev. 20(10), 1256–1261 (2006).
  Medline CASGoogle Scholar
• 22 Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 21(8), 920–928, (2007).
  Medline CASGoogle Scholar
• 23 Park J, Chen Y, Tishkoff DX et al. SIRT5 –mediated lysine desuccinylation impacts diverse metabolic pathways. Mol. Cell. 50(6), 919–930 (2013).
  Medline CASGoogle Scholar
• 24 Matsushita N, Yonashiro R, Ogata Y et al. Distinct regulation of mitochondrial localization and stability of two human Sirt5 isoforms. Genes Cells 16(2), 190–202 (2011).
  Medline CASGoogle Scholar
• 25 Sigrist CJ, de Castro E, Cerutti L et al. New and continuing developments at PROSITE. Nucl. Acids Res. 41, D344–D347 (2013).
  Medline CASGoogle Scholar
• 26 Choi J-E, Mostoslavsky R. Sirtuins, metabolism and DNA repair. Curr. Opin. Genet. Dev. 26, 24–32 (2014).•• Comprehensive and recent review of the crucial roles of sirtuins in the control of metabolism, and the link with their role in the DNA repair response.
  Medline CASGoogle Scholar
• 27 Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13(19), 2570–2580 (1999).
  Medline CASGoogle Scholar
• 28 Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410(6825), 227–230 (2001).
  Medline CASGoogle Scholar
• 29 Wood JG, Rogina B, Lavu S et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430(7000), 686–689 (2004).
  Medline CASGoogle Scholar
• 30 Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem. Sci. 32(12), 555–560 (2007).
  Medline CASGoogle Scholar
• 31 Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 27(19), 2072–2085 (2013).
  Medline CASGoogle Scholar
• 32 Cantò C, Auwerx J. NAD⁺ as a signaling molecule modulating metabolism. Cold Spring Harb. Symp. Quant. Biol. 76, 291–298 (2011).
  Medline CASGoogle Scholar
• 33 Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 9(2), 123–128 (2009).
  Medline CASGoogle Scholar
• 34 Ahn BH, Kim HS, Song S et al. A role for mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl Acad. Sci. USA 105(38), 4447–4452 (2008).
  MedlineGoogle Scholar
• 35 Vassilopoulos A, Pennington JD, Andresson T et al. SIRT3 deacetylates ATP synthase FA complex proteins in response to nutrient- and exercise-induced stress. Antioxid. Redox Signal. 21(4), 551–564 (2014).
  Medline CASGoogle Scholar
• 36 Jing E, O'Neill BT, Rardin MJ et al. Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes 62(10), 3404–3417 (2013).
  Medline CASGoogle Scholar
• 37 Du J, Zhou Y, Su X et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334(6057), 806–809 (2011).
  Medline CASGoogle Scholar
• 38 Park J, Chen Y, Tishkoff DX et al. Sirt5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol. Cell 50(6), 919–930 (2013).
  Medline CASGoogle Scholar
• 39 Mostoslavsky R, Chua KF, Lombard DB et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124(2), 315–329 (2006).
  Medline CASGoogle Scholar
• 40 Zhong L, Urso AD, Toiber D et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140(2), 280–293 (2010).
  Medline CASGoogle Scholar
• 41 Warburg O. On the origin of cancer cells. Science 123(3191), 309–314 (1956).
  Medline CASGoogle Scholar
• 42 Horemans AMC, Tielens AGM, van den Bergh SG. The reversible effect on the energy metabolism of Schistosoma mansoni cercariae and schistosomula. Mol. Biochem. Parasitol. 51(1), 73–80 (1992).
  Medline CASGoogle Scholar
• 43 Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 20(9), 1075–1080 (2006).
  Medline CASGoogle Scholar
• 44 Shin J, He M, Liu Y et al. Sirt7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 5(3), 654–665 (2013).
  Medline CASGoogle Scholar
• 45 Yohizawa T, Karim MF, Sato Y et al. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin proteasome pathway. Cell Metab. 19(4), 712–721 (2014).
  MedlineGoogle Scholar
• 46 Ryu D, Jo YS, Lo Sasso G et al. A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function. Cell Metab. 20(5), 856–869 (2014).
  Medline CASGoogle Scholar
• 47 Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl Acad. Sci. USA 104(31), 12861–12866 (2007)
  Medline CASGoogle Scholar
• 48 Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9(4), 327–338 (2009).
  Medline CASGoogle Scholar
• 49 Hirschey MD, Shimazo T, Goetzman E et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464(7285), 121–125 (2010).
  Medline CASGoogle Scholar
• 50 Laurent G, German NJ, Saha AK et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol. Cell 50(5), 686–698 (2013).
  Medline CASGoogle Scholar
• 51 Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 30(3), 546–555 (2010).
  MedlineGoogle Scholar
• 52 Jeong SM, Xiao C, Finley LW et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamate metabolism. Cancer Cell 23(4), 450–463 (2013).
  Medline CASGoogle Scholar
• 53 Scheibye-Knudsen M, Mitchell SJ, Fang EF et al. A high fat diet and NAD(+) activate Sirt1 to rescue premature aging in Cockayne syndrome. Cell Metab. 20(5), 840–855 (2014).
  Medline CASGoogle Scholar
• 54 Iwahara T, Bonasio R, Narendra V, Reinberg D. SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol. Cell. Biol. 32(24), 5022–5034 (2012).
  Medline CASGoogle Scholar
• 55 Marek M, Kannan S, Hauser AT et al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog. 9(9), e1003645 (2013).•• Validates schistosome HDAC8 as an epigenetic drug target and shows that schistosome-specific changes in the catalytic pocket should allow the development of selective inhibitors as drug leads.
  Medline CASGoogle Scholar
• 56 Finnin MS, Donigian JR, Pavletich NP. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 8(7), 621–625 (2001).
  Medline CASGoogle Scholar
• 57 Jin L, Wei W, Jiang Y et al. Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J. Biol. Chem. 284(36), 24394–24405 (2009).
  Medline CASGoogle Scholar
• 58 Schuetz A, Min J, Antoshenko T et al. Structural basis of inhibition of the human NAD⁺-dependent deacetylase SIRT5 by suramin. Structure 15(3), 377–389 (2007).
  Medline CASGoogle Scholar
• 59 Pan PW, Feldman JL, Devries MK, Dong A, Edwards AM, Denu JM. Structure and biochemical functions of SIRT6. J. Biol. Chem. 286(16), 14575–14587 (2011).
  Medline CASGoogle Scholar
• 60 Zhao X, Allison D, Condon B et al. The 2.5Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD⁺) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J. Med. Chem. 56(3), 963–969 (2013).
  Medline CASGoogle Scholar
• 61 Gertz M, Fischer F, Nguyen GT et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD⁺-dependent deacetylation mechanism. Proc. Natl Acad. Sci. USA 110(30), E2772–2781 (2013).
  Medline CASGoogle Scholar
• 62 Haigis MC, Mostoslavsky R, Haigis KM et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126(5), 941–954 (2006).
  Medline CASGoogle Scholar
• 63 Du J, Jiang H, Lin H. Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogs and ³²P-NAD. Biochemistry 48(13), 2878–2890 (2009).
  Medline CASGoogle Scholar
• 64 Mathias RA, Greco TM, Oberstein A et al. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell 159(7), 1615–1625 (2014).
  Medline CASGoogle Scholar
• 65 Jiang H, Khan S, Wang Y et al. SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496(7443), 110–113 (2013).
  Medline CASGoogle Scholar
• 66 Marek M, Oliveira G, Pierce RJ, Sippl W, Jung M, Romier C. Zinc-dependent erasers of protein acetylation in schistosomes: on the track of HDAC inhibitors as new antiparasitic drugs. Future Med. Chem. (2014) (In Press).
  Google Scholar
• 67 Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene 33(13), 1609–1620 (2014).
  Medline CASGoogle Scholar
• 68 Wang Z, Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer 4(3–4), 82–90 (2013).
  Medline CASGoogle Scholar
• 69 Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell 38(6), 864–878 (2010).
  Medline CASGoogle Scholar
• 70 Kim HS, Vassilopoulos A, Wang RH et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4), 487–499 (2011).
  Medline CASGoogle Scholar
• 71 Kim HS, Patel K, Muldoon-Jacobs K et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1), 41–52 (2010).
  Medline CASGoogle Scholar
• 72 Finley LW, Carracedo A, Lee J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1 alpha destabilization. Cancer Cell 19(3), 416–428 (2011).
  Medline CASGoogle Scholar
• 73 Csibi A, Fendt SM, Li C et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153(4), 840–854 (2013).
  Medline CASGoogle Scholar
• 74 Sebastián C, Zwaans BM, Silberman DM et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6), 1185–1199 (2012).
  Medline CASGoogle Scholar
• 75 Lu W, Zuo Y, Feng Y, Zhang M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumour Biol. 35(11), 10699–10705 (2014).
  Medline CASGoogle Scholar
• 76 Barber MF, Michishita-Kioi E, Xi Y et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487(7405), 114–118 (2012).
  Medline CASGoogle Scholar
• 77 Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11(5), 384–400 (2012).
  Medline CASGoogle Scholar
• 78 Wall KA, Klis M, Kornet J et al. Inhibition of the intrinsic NAD⁺ glycohydrolase activity of CD38 by carbocyclic NAD analogues. Biochem. J. 335(Pt 3) 631–636 (1998).
  Medline CASGoogle Scholar
• 79 Slama JT, Simmons AM. Inhibition of NAD glycohydrolase and ADP-ribosyltransferases by carbocyclic analogues of oxidized nicotinamide adenine dinucleotide. Biochemistry 28(19), 7688–7694 (1989).
  Medline CASGoogle Scholar
• 80 Schutkowski M, Fischer F, Roessler C, Steegborn C. New assays and approaches for discovery and design of Sirtuin modulators. Expert Opin. Drug Discov. 9(2), 183–199 (2014).
  Medline CASGoogle Scholar
• 81 Wang J, Kim TH, Ahn MY et al. Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int. J. Oncol. 41(3), 1101–1109 (2012).
  Medline CASGoogle Scholar
• 82 Lara E, Mai A, Calvanese V et al. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28(6), 781–791 (2009).
  Medline CASGoogle Scholar
• 83 Neugebauer RC, Sippl W, Jung M. Inhibitors of NAD⁺-dependent histone deacetylases (sirtuins). Curr. Pharm. Des. 14(6), 562–573 (2008).
  Medline CASGoogle Scholar
• 84 Cen Y. Sirtuin inhibitors: the approach to affinity and selectivity. Biochim. Biophys. Acta 1804(8), 1635–1644 (2010).
  Medline CASGoogle Scholar
• 85 Sauve AA, Schramm VL. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 42(19), 9249–9256 (2003).
  Medline CASGoogle Scholar
• 86 Schmidt MT, Smith BC, Jackson MD, Denu JM. Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J. Biol. Chem. 279(38), 40122–40129 (2004).
  Medline CASGoogle Scholar
• 87 Heltweg B, Gatbonton T, Schuler AD et al. Antitumor activity of a small molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66(8), 4368–4377 (2006).
  Medline CASGoogle Scholar
• 88 Suzuki T, Imai K, Nakagawa H, Miyata N. 2-Anilobenzamides as SIRT inhibitors. ChemMedChem 1(10), 1059–1062 (2006).
  Medline CASGoogle Scholar
• 89 Sanders BD, Jackson B, Brent M et al. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorg Med. Chem. 17(19), 7031–7041 (2009).
  Medline CASGoogle Scholar
• 90 Trapp J, Meier R, Hongwiset D, Kassak MU, Sippl W, Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD⁺-dependent histone deacetylases (sirtuins). ChemMedChem 2(10), 1419–1434 (2007).
  Medline CASGoogle Scholar
• 91 Trapp J, Jochum A, Meier R et al. Adenosine mimetics as inhibitors of NAD⁺-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem. 49(25), 7307–7316 (2006).
  Medline CASGoogle Scholar
• 92 Napper AD, Hixon J, McDonagh T et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48(25), 8045–8054 (2005).
  Medline CASGoogle Scholar
• 93 Uciechowska U, Schemies J, Neugebauer RC et al. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations and biological testing. ChemMedChem 3(12), 1965–1976 (2008).
  Medline CASGoogle Scholar
• 94 Outeiro TF, Kontopoulos E, Altmann SM et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837), 516–519 (2007).
  Medline CASGoogle Scholar
• 95 Sakai T, Matsumoto Y, Ishikawa M et al. Design, synthesis and structure-activity relationship studies of novel sirtuin 2(SIRT2) inhibitors with a benzamide skeleton. Bioorg. Med. Chem. 23(2), 328–339 (2015).
  Medline CASGoogle Scholar
• 96 Di Fruschia P, Zacharioudakis E, Liu C et al. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in and in vitro Parkinson's disease model. ChemMedChem 10(1), 69–82 (2015).
  MedlineGoogle Scholar
• 97 Cui H, Kamal Z, Ai T et al. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J. Med. Chem. 57(20), 8340–8357 (2014).
  Medline CASGoogle Scholar
• 98 Hirao M, Posakony J, Nelson M et al. Identification of selective inhibitors of NAD⁺-dependent deacetylases using phenotypic screens in yeast. J. Biol. Chem. 278(52), 52773–52782 (2003).
  Medline CASGoogle Scholar
• 99 Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276(42), 38837–38843 (2001).
  Medline CASGoogle Scholar
• 100 Mai A, Massa S, Lavu S et al. Design, synthesis and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48(24), 7789–7795 (2005).
  Medline CASGoogle Scholar
• 101 Kiviranta PH, Suuronen T, Wallen EA et al. N(epsilon)-thioacetyl-lysine-containing tri-, tetra- and pentapeptides as SIRT1 and SIRT2 inhibitors. J. Med. Chem. 52(7), 2153–2156 (2009).
  Medline CASGoogle Scholar
• 102 Suenkel B, Fischer F, Steegborn C. Inhibition of the human deacylase Sirtuin 5 by the indole GW5074. Bioorg. Med. Chem. Lett. 23(1), 143–146 (2013).
  Medline CASGoogle Scholar
• 103 Roessler C, Nowak T, Pannek M et al. Chemical probing of the human sirtuin 5 active site reveals its substrate acyl specificity and peptide-based inhibitors. Angew. Chem. Int. Ed. Engl. 53(40), 10728–10732 (2014).
  Medline CASGoogle Scholar
• 104 Maurer B, Rumpf T, Scharfe M et al. Inhibitors of the NAD(+)-dependent protein desuccinylase and demalonylase Sirt5. ACS Med. Chem. Lett. 3(12), 1050–1053 (2012).
  Medline CASGoogle Scholar
• 105 Disch JS, Evindar G, Chiu CH et al. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2 and SIRT3. J. Med. Chem. 56(9), 3666–3679 (2013).
  Medline CASGoogle Scholar
• 106 Schiedel M, Marek M, Lancelot J et al. Fluorescence-based screening assays for the NAD⁺-dependent histone deacetylase smSirt2 from Schistosoma mansoni. J. Biomol. Screen. 20(1), 112–121 (2015).• Describes assay methods developed for the high-throughput screening of a recombinant schistosome sirtuin.
  Medline CASGoogle Scholar
• 107 Duraisingh MT, Voss TS, Marty AJ et al. Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in Plasmodium falciparum. Cell 121(1), 13–24 (2005).
  Medline CASGoogle Scholar
• 108 Tonkin CJ, Carret CK, Duraisingh MT et al. Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol. 7(4), e84 (2009).
  MedlineGoogle Scholar
• 109 Vergnes B, Sereno D, Tavares J et al. Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation. Gene 363, 85–96 (2005).
  Medline CASGoogle Scholar
• 110 Vergnes B, Vanhille L, Ouaissi A, Sereno D. Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase. Acta Trop. 94(2), 107–115 (2005).
  Medline CASGoogle Scholar
• 111 Tavares J, Ouaissi A, Kong Thoo Lin P et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem 5(1), 140–147 (2010).
  Medline CASGoogle Scholar
• 112 Pierce RJ. Anti-parasitic drug discovery. Pan Europ. Networks Sci. Technol. 11, 192–193 (2014).
  Google Scholar